BioTrinity 2011 Keynotes and Panel Discussions - April 12-14, 2011
The details of panels and key notes presentations at BioTrinity 2012 will be announced here in the Autumn, sign up for our newsletter to keep informed.
Excellent plenary sessions and panel discussions took place at BioTrinity 2011, featuring senior licensing professionals and corporate venture arms of global pharma such as Merck, GSK, Boehringer Ingelheim, Merck Serono, Shire as well as VC's and Investment Banks such as Edmond de Rothschild, DFJ Esprit, Aelios Finance, Lucia Capital and others...
Our plenaries and panels feature international participation from professionals in the US, UK, Denmark, Germany, and Switzerland, with companies from over 10 countries represented among the audience.
The Panel Sessions will run along the following themes:
- “The Public Markets and Life Sciences: Experiences from the Frontline”
- “What's New in Corporate Venturing? Is Corporate Venture Replacing Traditional Venture?”
- “Successes During Crises: How Did They Make it Happen?”
- “Pharma Panel Discussion: Innovative Pharma Dealmaking”
- “Where will VC's Invest in 2012?”
- “Positioning your Company for Merger & Acquisition - Western and Chinese Perspectives” (Working Title)
|
Day One - Wednesday 13th April 2011 |
|
| 08:45-08:50 | Welcome and Opening Remarks: |
| Dr Jon Rees, CEO, OBN | |
| 08:50-09:00 | VIP Address: |
| Professor Colin Blakemore, Professor of Neuroscience, University of Oxford | |
|
|
|
| 09:00-09:45 | What's new in Corporate Venture? Is Corporate Venture Replacing Traditional Venture? |
| Panelists including many of the newer major CVCs (Corporate Venture Funds) representing global pharma venture arms as well as an "anti-CVC" will discuss why their big corporate parents wanted to get into Corporate Venture funding, the audience will learn what's new from established players, including geographically. The panel will discuss whether CVC can and will fill the gap left by traditional VC, and where the next wave of capital will come from, covering topics including whether CVCs can bring over their US syndicate partners to do deals in Europe, what it's like to have 3 corporates in your syndicate, and the types of companies that attract corporate venture funds.
|
|
 |
Deborah Harland, VP Partner, SR One (Chair) |
 |
Roel Bulthius, Head, Merck Serono Ventures |
 |
Gwen Melincoff, SVP Business Development, Shire Strategic Investment |
 |
Martin Heidecker, Investment Manager, Boehringer Ingelheim Venture Fund |
 |
Johan Kördel, Senior Investment Director, Lundbeckfond Ventures |
|
|
|
| 09:45-10:30 | Successes During Crises: How Did They Make it Happen? |
| Highly successful panelists chaired by Olivier Litzka from Edmond de Rothschild Investment Partners will discuss how they achieved their successes covering acquisition and IPO. Iain Buchanan will discuss how Sanofi spin-out Novexel was positioned for acquisition for £266m, Ernest Loumaye will discuss Preglem's acquisition by Richter for Euros 337m,Dirk Reyn will go into Movetis successful IPO raising Euros 85m and its subsequent sale to Shire plc for Euros 428m, while David Solomon will discuss Zealand's successful IPO which raised $60m before Christmas.
|
|
 |
Olivier Litzka, Partner, Edmond de Rothschild Investment Partners (Chair) |
 |
Iain Buchanan, CEO, NOXXON Pharma AG |
 |
Ernest Loumaye, CEO, Preglem SA |
 |
David H. Solomon, President & CEO, Zealand Pharma A/S |
|
Dirk Reyn, CEO, Shire-Movetis |
|
|
|
| 10:30-11:00 | Refreshments,Networking, Exhibition |
|
|
|
| 11:00-11:45 | Private Equity to Public Markets: Is AIM an Exit? |
| Panelists representing issuers, investors and corporate advisors will discuss their experiences of fundraising on the public markets, what investors want to see, what went wrong and what has gone well, the importance of cornerstone investors, as well as give tips to potential biotech issuers on how to do its successfully. The issuers featured include EKF Diagnostics Holdings plc (AIM: EKF) which recently acquired Quotient Diagnostics Ltd, and therapeutic vaccine company Scancell Holdings plc (AIM: SCLP) which listed on AIM in 2010.
|
|
 |
Tim Haines, Partner, Abingworth (Sponsor) |
 |
Raquel Hughes, Management Consultant (Chair) |
 |
James Steel, Director, Peel Hunt |
|
Andy Crossley, Corporate Broker, Peel Hunt |
 |
Richard Goodfellow, COO, Scancell Holdings plc |
|
John Aston, Former CFO, CAT |
|
|
|
| 11:45-12:30 | Positioning Your Company for Merger & Acquisition - Global Perspectives |
| Senior executives from big pharma and mid-cap biotech will explore their recent acquisitions and mergers, and discuss their experiences, including addressing the issue of whether M&A destroys innovation
|
|
 |
Fintan Walton, CEO, PharmaVentures (Chair) |
 |
Naiyin Wang, Investment Director, Shanghai Fosun Pharma |
 |
Bryan Morton, CEO, EUSA Pharma |
 |
Michael Brennan, Head of Corporate Development, Proximagen |
|
Sunil Shah, CEO, O2h |
|
|
|
|
Day Two - Thursday 14th April 2011 |
|
| 09:00-09:45 | Where Will VC's Invest in 2012? |
| Leading VCs all with funds to invest and the leading French corporate advisory firm will discuss where investors will invest in 2012. Investment firms participating will also highlight their recent key deals as well as describe their sweet spots for 2012.
|
|
 |
Charles Sermon, Partner, Phase4 Ventures (Chair) |
 |
Nigel Pitchford, Partner, DFJ Esprit |
|
Sofia Ioannidou, Associate, Edmond de Rothschild Investment Partners |
 |
Gunnar Weikert, Chairman, Inventages |
 |
Russ Cummings, Chief Investment Officer, Imperial Innovations |
 |
Alain Lostis, General Partner, Aelios Finance |
|
|
|
| 09:45-10:30 | Pharma Panel Discussion: Innovative Pharma Deal Making |
| Senior executives from leading pharma companies will be discussing their key deals and innovative business models that could be game changers, driving new value for the pharma & biotech industry. Panelists will discuss Key deals from the last 24 months, changes and innovations in their deal making, what opportunities each pharma company is currently looking for, and new and innovative business models which will enable more creative dealmaking moving forward including the changing role of corporate venture financing.
|
|
|
Tibor Papp, Head of Corporate Advisory, Pharma Ventures (Chair) |
 |
Margaret Beer, Senior Director and Head Licensing and External Research, Europe, MSD |
 |
Nicola Thompson, Director Scientific Opportunities, GSK-CEEDD |
 |
Philip Oliver, Executive Director, Global External R&D, Europe and MENA, Eli Lilly (Invited) |
 |
Christopher Berry, Contracting, Partnering & Innovation, sanofi aventis |
 |
Shaun Grady, VP Strategic Partnering and Business Development, AstraZeneca |
|
|
|
| 10:30-11:00 | Refreshments,Networking, Exhibition |
|
|
|
| 11:00-11:15 | Keynote Address: |
| Dr Richard Seabrook, Head of Business Development, The Wellcome Trust | |
| 11:15-11:30 | Keynote Address: |
| Dr Jon Rees, CEO, OBN | |
|
|
|
